Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study
Digestive Diseases and Sciences · 2025-02 · 70 (2) · 835-842
DOI: 10.1007/s10620-024-08667-4 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 09.10.2024. Verfasst von Virendra Singh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. virendrasingh100@hotmail.com. Hauptthemen laut MEDLINE: Ascites, Benzhydryl Compounds, Glucosides, Liver Cirrhosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. virendrasingh100@hotmail.com.
- Punjab Institute of Liver and Biliary Sciences, Mohali, India. virendrasingh100@hotmail.com.
- Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Albert Einstein Healthcare Network, Philadelphia, USA.
Zitieren
APA
Singh, V., De, A., Aggrawal, R., Singh, A., Charak, S., & Bhagat, N. (2025). Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study. Digestive Diseases and Sciences, 70(2), 835-842. https://doi.org/10.1007/s10620-024-08667-4
Vancouver
Singh V, De A, Aggrawal R, Singh A, Charak S, Bhagat N. Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study. Digestive Diseases and Sciences. 2025;70(2):835-842. doi:10.1007/s10620-024-08667-4
BibTeX
@article{Singh2025,
author = {Singh, Virendra and De, Arka and Aggrawal, Rishav and Singh, Akash and Charak, Swati and Bhagat, Naveen},
title = {Safety and Efficacy of Dapagliflozin in Recurrent Ascites: A Pilot Study},
journal = {Digestive Diseases and Sciences},
year = {2025},
volume = {70},
number = {2},
pages = {835--842},
doi = {10.1007/s10620-024-08667-4}
}
EUVIMED